Literature DB >> 8194165

Inhibition of dihydropyrimidine dehydrogenase by alpha-interferon: experimental data on human tumor cell lines.

G Milano1, J L Fischel, M C Etienne, N Renée, P Formento, A Thyss, M H Gaspard, L Thill, D Cupissol.   

Abstract

Interferons (IFNs) are very promising fluorouracil (FU) biochemical modulators. The pharmacological origin sustaining the FU-IFN synergistic interaction is not clearly understood. It was recently shown that alpha-IFN was associated with a dose-dependent decrease in FU clearance in treated patients. Dihydropyrimidine dehydrogenase (DPD) is the key regulating enzyme for FU catabolism. The effects on DPD exerted by both the IFN dose and the duration of exposure were evaluated in a panel of five human cancer cell lines. All cell lines investigated exhibited quantifiable DPD activity with inter-cell-line variability (0.118-0.318 nmol min-1 mg protein-1). A prolonged exposure to IFN (up to 5 days) was necessary to obtain a significant inhibition of DPD activity. A concentration-dependent significant decrease in DPD activity, reaching 50% of the initial activity determined for the highest IFN concentration (10(5) IU/ml), was demonstrated in all cell lines tested (5-day IFN exposure). For three cell lines, IFN potentiated the FU-induced growth inhibition in a concentration-dependent manner. Considering all cell lines and all IFN concentrations, it appears that globally, the greater the inhibition of DPD activity, the greater the FU potentiation (Spearman rank correlation on all cell lines, P = 0.011).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8194165     DOI: 10.1007/bf00685932

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  25 in total

Review 1.  Interferon therapy in cancer: from imaginon to interferon.

Authors:  D Goldstein; J Laszlo
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

Review 2.  Role of thymidine in biochemical modulation: a review.

Authors:  P J O'Dwyer; S A King; D F Hoth; B Leyland-Jones
Journal:  Cancer Res       Date:  1987-08-01       Impact factor: 12.701

3.  Rapid catabolism of 5-fluorouracil in freshly isolated rat hepatocytes as analyzed by high performance liquid chromatography.

Authors:  J P Sommadossi; D A Gewirtz; R B Diasio; C Aubert; J P Cano; I D Goldman
Journal:  J Biol Chem       Date:  1982-07-25       Impact factor: 5.157

Review 4.  Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma.

Authors:  M A Poon; M J O'Connell; C G Moertel; H S Wieand; S A Cullinan; L K Everson; J E Krook; J A Mailliard; J A Laurie; L K Tschetter
Journal:  J Clin Oncol       Date:  1989-10       Impact factor: 44.544

5.  Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma.

Authors:  S Wadler; E L Schwartz; M Goldman; A Lyver; M Rader; M Zimmerman; L Itri; V Weinberg; P H Wiernik
Journal:  J Clin Oncol       Date:  1989-12       Impact factor: 44.544

6.  Two new human tumor cell lines derived from squamous cell carcinomas of the tongue: establishment, characterization and response to cytotoxic treatment.

Authors:  J Gioanni; J L Fischel; J C Lambert; F Demard; C Mazeau; E Zanghellini; F Ettore; P Formento; P Chauvel; C M Lalanne
Journal:  Eur J Cancer Clin Oncol       Date:  1988-09

7.  Pharmacokinetics of 5-fluorouracil in colorectal cancer patients receiving interferon.

Authors:  K Pittman; T Perren; U Ward; J Primrose; M Slevin; N Patel; P Selby
Journal:  Ann Oncol       Date:  1993-06       Impact factor: 32.976

8.  Phase I and plasma pharmacokinetic study of infusional fluorouracil combined with recombinant interferon alfa-2b in patients with advanced cancer.

Authors:  L L Danhauser; J H Freimann; T L Gilchrist; J U Gutterman; C Y Hunter; A C Yeomans; A B Markowitz
Journal:  J Clin Oncol       Date:  1993-04       Impact factor: 44.544

9.  Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.

Authors:  E E Vokes; M J Ratain; R Mick; J M McEvilly; D Haraf; M Kozloff; V Hamasaki; R R Weichselbaum; W R Panje; B Wenig
Journal:  J Clin Oncol       Date:  1993-02       Impact factor: 44.544

10.  Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells.

Authors:  K Keyomarsi; R G Moran
Journal:  Cancer Res       Date:  1986-10       Impact factor: 12.701

View more
  2 in total

1.  DPYD, down-regulated by the potentially chemopreventive agent luteolin, interacts with STAT3 in pancreatic cancer.

Authors:  Hiroyuki Kato; Aya Naiki-Ito; Shugo Suzuki; Shingo Inaguma; Masayuki Komura; Kenju Nakao; Taku Naiki; Kenta Kachi; Akihisa Kato; Yoichi Matsuo; Satoru Takahashi
Journal:  Carcinogenesis       Date:  2021-07-16       Impact factor: 4.944

2.  Regulation of dihydropyrimidine dehydrogenase and pyrimidine nucleoside phosphorylase activities by growth factors and subsequent effects on 5-fluorouracil sensitivity in tumor cells.

Authors:  M Ueda; K Kitaura; O Kusada; Y Mochizuki; N Yamada; Y Terai; K Kumagai; K Ueki; M Ueki
Journal:  Jpn J Cancer Res       Date:  2000-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.